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ABSTRACT 
An important hallmark of various neurodegenerative disorders is the proliferation and activation of 
microglial cells, the resident immune cells of the central nervous system (CNS). Mice that lack 
multifunctional protein-2 (MFP2), the key enzyme in peroxisomal β-oxidation, develop excessive 
microgliosis that positively correlates with behavioral deficits whereas no neuronal loss occurs. 
However, the precise contribution of neuroinflammation to the fatal neuropathology of MFP2 deficiency 
remains largely unknown. Here, we first attempted to suppress the inflammatory response by 
administering various anti-inflammatory drugs but they failed to reduce microgliosis. Subsequently, 
Mfp2-/- mice were treated with the selective colony-stimulating factor 1 receptor (CSF1R) inhibitor 
PLX5622 as microglial proliferation and survival is dependent on CSF1R signaling.  This resulted in the 
elimination of more than 95% of microglia from control mice but only 70% of the expanded microglial 
population from Mfp2-/- mice. Despite microglial diminution in Mfp2-/- brain, inflammatory markers 
remained unaltered and residual microglia persisted in a reactive state. CSF1R inhibition did not prevent 
neuronal dysfunction, cognitive decline and clinical deterioration of Mfp2-/- mice. Collectively, the 
unaltered inflammatory profile despite suppressed microgliosis, concurrent with persevering clinical 
decline strengthens our hypothesis that neuroinflammation importantly contributes to the Mfp2-/- 
phenotype.           
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INTRODUCTION 
Peroxisomes and peroxisomal β-oxidation in particular are essential for the formation and maintenance 
of the CNS as deficits cause devastating neurological diseases in men and mice [1-3]. However, the 
precise molecular mechanisms remain elusive. The most common neurometabolic disorder caused by 
peroxisomal β-oxidation deficiency is X-linked adrenoleukodystrophy [4], characterized by myelopathy 
and, in a subgroup of patients, by fatal cerebral inflammatory demyelination. Although in the latter 
microglia seem to play a pivotal role in disease progression [5, 6], this cannot be further investigated in 
the corresponding mouse model (Abcd1-/-) as only spinal cord pathology develops [4]. We have 
generated and analyzed mouse models with constitutive and cell type-selective deletion of 
multifunctional protein-2 (MFP2, also known as D-bifunctional protein and HSD17B4), the pivotal 
enzyme of peroxisomal β-oxidation [7-9]. In contrast to Abcd1-/- mice, Mfp2-/- mice develop excessive 
neuroinflammation from the age of 6 weeks that worsens with age [7, 9, 10]. Mfp2-/- mice exhibit 
progressive motor deficits and lethargy and die before the age of 6 months [9, 10]. This phenotype does 
not correspond with the severe neurodevelopmental pathology of patients with total ablation of MFP2 
[11], but rather mimics milder mutations in patients that give rise to neurological anomalies including 
ataxia, leukodystrophy and vision/hearing problems [11-13].  
The microgliosis in Mfp2-/- mice, characterized by increased microglial numbers and morphological 
transformation, exclusively depends on the proliferation of resident cells [7]. The expansion of the 
microglial population positively correlates with the severity of neuronal dysfunction and clinical 
deterioration (Beckers and Baes, unpublished data) but the underlying sequence of pathological events 
is poorly understood. Microgliosis is confined to gray matter areas and Mfp2-/- microglia surround 
neurons, indicating a pathological role of disturbed microglia-neuron communication in MFP2 
deficiency. Despite affected neuronal transmission and clinical deterioration in Mfp2-/- mice, there is no 
obvious loss of neuron numbers ([7], Beckers and Baes, unpublished data).  
An outstanding question is how chronic microgliosis and aberrant phenotype of Mfp2-/- microglia impact 
on neuronal dysfunction and murine behavioral deficits. Therefore, we first attempted to suppress 
neuroinflammation by using agents that were successfully used in neurodegenerative diseases to 
reduce microglial reactivity and pro-inflammatory markers i.e. minocycline [14, 15], pioglitazone [16, 17] 
and 5-androsten-3β,17β-diol (ADIOL) [18]. Because these treatments failed to improve the 
inflammatory state of the brain and the clinical deterioration of the mice, we subsequently tried to 
specifically eradicate microglia from Mfp2-/- brain. It was previously shown that microglia in the adult 
brain are utterly dependent on CSF1R signaling for their survival and maintenance [19, 20]. Accordingly, 
administration of CSF1R inhibitors that cross the blood-brain barrier were shown to cause brain-wide 
elimination (90-98%) of microglia within 7 days of treatment without altering circulating monocyte 
numbers [21, 22]. Moreover, eliminating microglia in neurodegenerative diseases such as Alzheimer’s 
disease (AD) prevents neuronal loss and improved performance in memory and behavioral tasks [23-
28]. Specific microglial depletion has never been tested in neurometabolic or non-neurodegenerative 
disorders. Hence, we treated Mfp2-/- and control mice for 10 weeks with the CSF1R inhibitor PLX5622. 
We found that this compound effectively eliminated all microglia from control brain but only significantly 
reduced and did not obliterate the activated microglia from Mfp2-/- brain. Pharmacological targeting of 
Pioglitazone Vehicle  Vehicle 
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CSF1R could not prevent the clinical deterioration nor improve neuronal dysfunction and cognition of 
Mfp2-/- mice.  
 
 
 
MATERIALS AND METHODS 
Mouse breeding 
The generation of Mfp2-/- mice has been described [29] but mice were now bred into a C57BL/6J 
background for seven generations. As we did not detect differences between wild type and 
heterozygous mice in our previous investigations, they were both used as controls. Genotyping was 
performed on tail DNA. All mice were bred in the animal housing facility of the KU Leuven, had ad 
libitum access to water and standard rodent food, and were kept on a 12-hour light and dark cycle. All 
experiments were conducted in accordance with "Guidelines for Care and Use of Experimental 
Animals" and fully approved by the Research Ethical committee of the KU Leuven (#190/2012, 
#181/2015). 
 
Administration of anti-inflammatory drugs 
Minocycline (50 mg/kg, Abc chemicals, Wouters-Brakel, Belgium) or PBS was administered by daily 
intraperitoneal injection [30] from the age of 9 weeks till the age of 15 weeks. Pioglitazone hydrochloride 
(sc-204848, Santa Cruz Biotechnology) was formulated with normal mouse chow and gelatin at 240 
ppm. The same diet but containing vehicle was used as control. Briefly, normal chow was pulverized 
and thoroughly mixed with either pioglitazone hydrochloride or vehicle.  Gelatin was dissolved in hot 
water (below boiling point) and mixed with pulverized chow. The food chunks were kept at 4°C for at 
least 2 hours. Control and Mfp2-/- mice (n = 7-8/group) were fed the diets from the age of 10 weeks till 
the age of 15 weeks. Every 2-3 days, chow was renewed and food intake was measured. Clinical scores 
were weekly determined throughout the treatment period and prior to sacrifice.  
 
Administration of PLX5622 
PLX5622 was provided by Plexxikon Inc. and formulated in AIN-76A standard chow by Research Diets 
Inc. at 1200 ppm. The same diet containing vehicle was used as control. Control and Mfp2-/- mice (n = 
9/group) were fed the diets from the age of 6 weeks till the age of 16 weeks. Clinical scores were 
determined throughout the treatment period and behavioral studies were conducted prior to sacrifice.  
 
Murine behavioral studies 
Auditory brainstem response test. Brainstem auditory-evoked potentials (BAEPs) were recorded on a 
Myos 4 plus digital EMG/EP recorder (Schwarzer, Munich, Germany). Mice were anesthetized with 
Nembutal (6 mg/ml i.p. at 1 % body weight). A needle electrode was placed subcutaneously behind 
each ear and referenced to a common electrode near the base of the tail; a fourth electrode, also placed 
near the base of the tail, was used as a ground. Robust five-peak tracings were obtained by averaging 
2000 responses evoked by 85-86 dB clicks [measured with a Brüel & Kjær (Norcross, GA) sound 
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intensity meter] emitted by a speaker placed 1 cm in front of the animal's head. For each of the tracings, 
latencies of the first five peaks (numbered I through V) were measured as well as interpeak latencies I-
III, III-V, and I-V. In addition, mean amplitudes of all peaks were measured.  
 
Exploration by Open Field (OF) assessment. OF exploration was tested in a brightly illuminated 50 cm 
× 50 cm square arena subsequent to 30 min of dark adaptation. Movements in the arena were video-
tracked for 10 min. Total path length, distance to the center and number of corner entries were 
assessed. 
 
Passive Avoidance (PA) learning. PA learning was examined in a cage consisting of a light and a dark 
compartment containing a grid floor [31]. After 30 min adaptation to the dark, the mouse was placed in 
the light compartment for a training trial. After 5 s, the dark compartment was opened and step-through 
latency was manually recorded. When all paws were placed on the grid floor, a mild electric footshock 
(0.2 mA, 2 s) was applied. Retention was tested 24 h later in the dark-adapted mouse, and latency to 
enter the dark compartment was measured up to a 300-s cut-off value. 
 
Clinical score. Progression of disease was assessed and scored based on the severity of typical clinical 
symptoms including ataxia, gait disturbance, weakness, alertness/activity, cataract and kyphosis. 
Kyphosis is a condition in which the thoracic spine has an excessive outward curvature, causing 
hunching of the back. Scores from 0 to 5 were assigned according to severity of each symptom. A score 
of 0 was given to mice that were normal. A higher score was given if the symptom was more severe. 
The clinical score value is the sum of all scores from distinct symptoms. 
 
Grip strength measurement. The grip strength test measures either the forepaw strength or a combined 
forepaw and hind paw strength. Mice were allowed to grasp the grip strength meter grid with their 
forepaws only, and were then gently pulled from the base of the tail until they release the grip. The grip 
strength meter measures the maximum force applied to the meter. This was repeated 5 times per 
mouse. Afterwards, grip strength of combined forepaw and hind paw strength were measured by 
repeating the protocol but placing the mouse with four paws on the grid before pulling it gently from the 
base of the tail. 
 
Inverted grid test. The inverted grid test or four limb hang test is a test of combined forepaw and hind 
paw strength. Mice are placed on a wire grid which is then inverted. The latency to fall is recorded with 
a time limit of 300 s. In general, normal mice are able to remain on the inverted grid for at least 300 s. 
Mice that fall off the grid before the time limit of 300 s were directly given one more try. Mice that hang 
for the 300 s limit were placed back in the cage. 
 
Immunohistochemistry 
Mice were anesthetized with a mix of Dormitor (1 mg/kg) and Nimatek (75 mg/kg). Tissue processing 
and IHC staining were performed as described [9, 32, 33]. Briefly, mice were perfused transcardially 
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with PBS (pH 7.4) followed by 4% paraformaldehyde (PFA). Brains were isolated, post-fixed with 4% 
PFA overnight, and kept in 70% ethanol prior to paraffin embedding. Routinely, paraffin sections (7 µm) 
were used for immunofluorescent stainings. The following primary antibodies were used: polyclonal 
rabbit anti-IBA1 (1:500; Wako D19-19741), rat anti-F4/80 (1:500; Serotec, Oxford, UK). After incubation 
with primary antibodies overnight at room temperature HRP-labeled secondary antibodies (1:200) were 
applied for 1 hour, followed by fluorescent labeling with a cyanine 2 (FITC) TSA kit (Perkin Elmer Life 
sciences, Boston, USA). When double immunolabeling was performed, sets of primary and secondary 
antibodies were applied sequentially. As second fluorescent labels, cyanine 3 TSA kits (Perkin-Elmer) 
were used. Images were acquired with a motorized inverted IX-81 microscope connected to a CCD-
FV2T digital camera (Olympus, Aartselaar, Belgium) and processed with LSM Image browser software 
(Zeiss, Germany).  
 
Quantification of IHC staining 
Cell number quantification. Microglia cell numbers were quantified on paraffin sections (7 µm) that were 
immunofluorescently stained using IBA1 antibodies. Cells were counted around the sagittal midline or 
coronal plane at the height of different brain areas. Within one plane (20 x magnification), only IBA1-
positive cells that 1) fully colocalized with DAPI-positive nuclei, and 2) had a clear cell soma and at least 
two clear protrusions were counted in the different regions of the brain. Microglia number per frame was 
corrected for surface area. Mfp2-/- and control mice of different ages were used (n=4-5/group). 
 
Fluorescence intensity quantification. IBA1 immunofluorescence intensity was measured in different 
brain regions such as brainstem, visual cortex and thalamus within one plane of 4 x magnification. Using 
the Image J software (Fiji), channels were first split, background signal was subtracted by selecting an 
area of the section that expressed noise fluorescence, the area of interest was selected, and mean gray 
value was subsequently measured at the same area size per brain region. 
 
Real-time quantitative PCR (RT-qPCR) 
Total RNA was isolated from brain tissue using Trizol reagent (Invitrogen, California, USA). 
Subsequently, cDNA was generated from 1 µg RNA using the QuantiTect Reverse Transcription Kit 
(QIAGEN, Venlo, The Netherlands). Real time PCR was performed as previously described [33] using 
an ABI PRISM 7500 Real Time PCR instrument (Applied Biosystems, Lennik, Belgium). Primers and 
probes were either designed using Primer Express Software (Applied Biosystems) or ordered from 
Applied Biosystems as premade Taqman Gene Expression assays (Il1b, Mm011336189_m1; Tnfa, 
Mm.PT.58.12575861; Cx3cr1, Mm0262011_s1; Tlr2, Mm.PT.58.45820113; Tspo, 
Mm.PT.58.43313736; F4/80 or Emr1, Mm.PT.58.11087779; Cholesterol 25-hydroxylase (25OHChol), 
Mm.PT.58.42792394). Mouse Aif primer (Mm00479862_g1) was ordered from Life Technologies (Gent, 
Belgium). Assays were performed in duplicate or triplicate in 10 µL TaqMan Fast Universal PCR Master 
Mix (Applied Biosystems). Relative expression levels of the target genes were calculated taking into 
account the amplification efficiency as described [34]. The relative expression levels of the target genes 
were calculated as a ratio to the housekeeping gene β-actin.  
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Statistical analyses 
All data except some behavioral tests were analyzed with GraphPad Prism software (version 5.0 and 
6.0, San Diego, CA). Statistical analyses were carried out using unpaired and paired, two-sided 
Student’s t-test, one-way ANOVA, two-way ANOVA or two-way repeated measures (RM) ANOVA 
followed by the Bonferroni post hoc test. Data are shown as mean ± Standard Error of the Mean (SEM) 
and statistical significance was set at p < 0.05. SPSS Statistics software was used for three-way 
ANOVA and three-way RM ANOVA  
BAEP test. Three-way RM ANOVA with genotype, age, and peak as sources of variation and two-way 
RM ANOVA per age with genotype and peak as sources of variation were used to evaluate disease 
progression of Mfp2-/- mice. Two-way ANOVA with age and model as independent variables was used 
for evaluation of interpeak latencies.  
OF and PA test. Two-way ANOVA with genotype and age as sources of variation was used to evaluate 
disease progression of Mfp2-/- mice. Subsequently, performance of Mfp2-/- mice (expressed relative to 
their respective wildtype values) was directly compared using two-way ANOVA with age and model as 
independent variables. 
The Holm-Sidak and Bonferroni method was used for multiple comparisons. Independent samples t-
test was used to compare performance at pathological end stages.  
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RESULTS 
Failure of anti-inflammatory drugs to suppress neuroinflammation  
In order to determine whether microgliosis contributes to CNS pathology in Mfp2-/- mice, we first 
attempted to suppress neuroinflammation by administering anti-inflammatory drugs. Minocycline, 
previously shown to be neuroprotective through its anti-inflammatory activity in neurodegenerative 
disease mouse models [14, 15, 30] was administered for 6 weeks. Brains of Mfp2-/- and control mice 
were analyzed by IHC detecting the microglial marker IBA1. As previously shown, IBA1 
immunoreactivity is increased in different CNS areas of Mfp2-/- compared to control mice, consistent 
with development of extensive microgliosis. However, minocycline treatment was unable to reduce 
microgliosis in Mfp2-/- mice (Fig. 1A). Also the PPARγ agonist pioglitazone, known to ameliorate 
Parkinson’s and Alzheimer’s disease models by reducing inflammation [16, 17] was ineffective in 
decreasing IBA1 immunoreactivity (Fig. 1B). In addition, modified transcript levels of inflammatory 
markers Tnfa, Mpeg1, Il6, Il1b and Arg1 in Mfp2-/- brain [7] were unaltered after pioglitazone treatment 
(Data not shown). Finally, ADIOL shown to prevent experimental autoimmune encephalomyelitis by 
regulating inflammatory responses in microglia [18] did not change microglial reactivity in the Mfp2-/- 
brain (not shown). During all anti-inflammatory treatments, clinical scores based on weight, gait, ataxia, 
alertness, cataract, and kyphosis were weekly measured, but no significant differences between treated 
and untreated mice in both genotypes were detected (shown for pioglitazone in Fig. 1C). Accordingly, 
treatments with these anti-inflammatory drugs were unable to ameliorate the severe neurological 
phenotype and clinical deterioration of Mfp2-/- mice. Therefore, we searched for other strategies to 
eliminate microglia specifically.  
 
 
CSF1R inhibition depletes microglia 
Although we have previously documented microglial proliferation in MFP2 deficiency [7], the pro-
mitogenic factors involved were not defined. Microglia in the adult brain are dependent on CSF1R 
signaling for their survival. During neurodegeneration, it was shown that the ligands of CSF1R, namely 
CSF1 and especially IL-34, induce microglial proliferation [21, 25, 35]. Analysis of transcript levels in 
brain tissue demonstrated elevated expression of Il34 (7.7-fold) but not of Csf1 in Mfp2-/- mice compared 
to control mice at 3 months of age (Fig.2A,B).  
Given the increased Il34-CSF1R signaling in Mfp2-/- brain, we attempted to eliminate microglia by 
administering PLX5622, an orally bioavailable selective CSF1R inhibitor that crosses the blood-brain 
barrier [22, 36, 37]. PLX5622 was mixed into standard rodent chow at 1200 ppm and administered to 
6-weeks-old Mfp2-/- and control mice for a period of 10 weeks. PLX treatment depleted nearly all IBA+ 
microglia in control brain (shown for brainstem in Fig. 3A,B; for visual cortex at a higher magnification 
in Fig. 3H,I) and markedly diminished the microglial response in Mfp2-/- brain (shown for brainstem in 
Fig. 3C,D and visual cortex Fig. 3J,K). In the latter, the remaining microglia exhibited an enlarged 
morphology with thickened protrusions (Fig. 3K). Quantification of IBA1 fluorescence in different brain 
regions of control mice verified an 80%, 94% and 93% reduction in brainstem, visual cortex and 
thalamus, respectively (Fig. 3E-G). In Mfp2-/- brain, the PLX5622 reduced IBA1 fluorescence by 66%, 
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72% and 57% in brainstem, visual cortex and thalamus, respectively (Fig. 3E-G). Quantification of IBA1+ 
cell numbers revealed a 95-98% reduction in control brain, and a 70-73% reduction in Mfp2-/- brain (Fig. 
3L,M, shown for brainstem and visual cortex). In summary, PLX treatment significantly reduced, but 
could not irradicate microglia in Mfp2-/- mice, suggesting that CSF1R signaling is important for the robust 
microgliosis. The residual microglia in PLX-treated Mfp2-/- mice still display a reactive morphology.  
 
CSF1R inhibition diminishes expression of microglial activation markers, but does not affect 
astrogliosis 
To further define microglial features, transcript levels of microglia-related genes were analyzed in 
brainstem of Mfp2-/- and control mice treated with PLX or vehicle. Transcripts of the general marker 
Iba1, the homeostatic marker Cx3cr1 and the activation marker F4/80 were significantly increased in 
Mfp2-/- mice as compared to control mice. After PLX treatment, microglial transcript levels were reduced 
by 80% (Iba1), 82% (Cx3cr1), and 71% (F4/80) in control brainstem whereas this reduction was less 
pronounced in Mfp2-/- brainstem being 44% (Iba1), 57% (Cx3cr1), and 32% (F4/80) (Fig. 4A-C).  
Apart from reduced gene expression after PLX treatment, we determined whether F4/80 activation was 
also reduced at the protein level by IHC analysis. F4/80+ cells are not detectable in control brain (not 
shown), but we found a significant reduction of F4/80 activation in the entire Mfp2-/- brain after PLX 
treatment (Fig. 4D,E). However, F4/80+ cells were not completely eliminated (Fig.4E), which confirms 
that PLX treatment could only diminish the strongly activated phenotype of Mfp2-/- microglia. 
Microgliosis is associated with astrogliosis in CNS pathologies and it is hypothesized that 
immunologically activated microglia initiate and maintain astrogliosis [38]. To determine whether PLX 
treatment impacts on astrogliosis in Mfp2-/- brain [9], IHC for the astroglial marker GFAP was performed. 
We found increased immunoreactivity throughout the Mfp2-/- brain as compared to controls (not shown), 
but PLX treatment did not affect number nor shape of GFAP+ cells in any brain region (Fig. 4F,G). 
Taken together, the results demonstrate that PLX treatment specifically downregulates but does not 
deplete microglial markers whereas astroglial markers remain unaffected in Mfp2-/- mice. 
 
 
CSF1R inhibition cannot reverse the inflammatory response in the brain 
To explore how microglial depletion affects the inflammatory state of the brain, several immune-related 
genes were analyzed in Mfp2-/- and control brainstem after PLX or vehicle treatment. Transcript levels 
of pro-inflammatory markers Tnfa, Il1b, Tlr2 and 25OHChol, and the general inflammatory marker Tspo 
were significantly increased in vehicle-treated Mfp2-/- relative to control brain (Fig. 5A-E). After PLX 
treatment, transcript levels of Tnfa and Il1b were significantly downregulated in control brain. 
Surprisingly, none of the transcripts were significantly changed in PLX-treated versus vehicle-treated 
Mfp2-/- mice (Fig. 5A-E). Thus, despite the substantial reduction in numbers of microglia, CSF1R 
inhibition cannot prevent the development of an inflamed brain. 
 
 
Depletion of microglia does not improve clinical score and grip strength 
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Mice were clinically evaluated on a weekly base by measurements of weight, grip strength, and clinical 
score to identify whether microglial diminution impacts the clinical phenotype and performances of Mfp2-
/- mice. Clinical scores were given based on general activity, gait, ataxia, kyphosis, and cataract. Mfp2-
/- mice show an early-onset decreased weight [9, 29], but there were no significant differences observed 
between PLX- and vehicle-treated animals (Fig. 6A). Worsening of clinical scores with age ran parallel 
between PLX- and vehicle-treated Mfp2-/- mice (Fig. 6B). In addition, PLX treatment did not improve 
decreased grip strength of both front paws (Fig. 6C) and all paws together (Fig. 6D). We previously 
showed that Mfp2-/- mice are not able to remain hanging on an inverted grid (Beckers and Baes, 
unpublished observations). Comparison of PLX-treated with vehicle-treated mice revealed that PLX-
treated Mfp2-/- mice similarly fail to retain on the inverted grid (Fig. 6E). Based on these results, we 
conclude that CSF1R inhibition and subsequent reduced microglial numbers did not halt nor delay 
clinical deterioration of Mfp2-/- mice. 
 
 
Microglial depletion did not prevent behavioral and cognitive impairment 
Given the result that significant reduction of microglia did not reduce the inflammatory state of the brain 
nor improve the clinical phenotype of Mfp2-/- mice, we sought to determine whether PLX treatment could 
prevent behavioral anomalies. Therefore, prior to sacrifice at 16 weeks of age, fear conditioning as an 
index of learning ability was assessed by means of the passive avoidance (PA) test. The test phase is 
preceded by a training phase during which mice received punishment to learn to avoid an aversive 
context. Training phase was not shown as there were no significant differences between genotypes 
and treatments. During the test phase, Mfp2-/- mice treated with PLX stepped as quickly into the room 
delivering the electroshock compared to vehicle treated mutants whereas the control mice had learned 
to avoid the shock, indicating that PLX treatment could not prevent the cognitive decline (Fig. 7A). 
Notably, PLX-treated control mice performed significantly better in the PA test compared to vehicle-
treated control mice (Fig. 7A). 
Locomotor activity and explorative behavior were assessed by video-tracking mice in an open field (OF) 
environment. There was no change in corner entries (Fig. 7B) in PLX- versus vehicle-treated mice which 
shows that PLX treatment could not improve locomotor activity in Mfp2-/- mice. We previously defined 
that Mfp2-/- mice spent increased time in the center and showed a decreased average distance to center 
as indications of disturbed explorative behavior (Beckers and Baes unpublished data). PLX treatment 
could not avoid disturbed explorative behavior in Mfp2-/- mice shown by similarly increased time in 
center (Fig.7C) and decreased distance to center (Fig. 7D) compared to vehicle-treated mice. 
In summary, microglial diminution by PLX treatment in Mfp2-/- mice was not able to prevent disturbed 
locomotion, exploration and cognition. 
 
Depletion of microglia did not prevent dysfunctional neuronal transmission 
BAEP recordings revealed previously that Mfp2-/- mice exhibit delayed neuronal transmission and 
decreased amplitudes of the auditory signal (Beckers and Baes, unpublished data). As severity of 
neuronal dysfunction is correlated with the extent of microgliosis, we wanted to discern whether CSF1R 
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inhibition improves neuronal functioning in the Mfp2-/- brain. Therefore, auditory brainstem responses 
were conducted in Mfp2-/- and control mice after 10 weeks of PLX or vehicle treatment. We found that 
mean peak latencies were not changed by PLX treatment compared to vehicle treatment in both control 
(Fig. 8A) and Mfp2-/- (Fig. 8B) mice. This was confirmed by direct comparison of PLX-treated Mfp2-/-  
with PLX-treated control mice that reveals significant delayed peak responses in PLX-treated Mfp2-/-  
versus control mice (Fig. 8C), consistent with our previous non-treatment data (Beckers and Baes, 
unpublished). Furthermore, PLX treatment did not affect the reduced amplitudes in Mfp2-/- mice (Fig. 
8D). 
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DISCUSSION 
The key feature of pathology in Mfp2-/- mice is the development of strong and progressive microgliosis. 
The consequences and impact of this innate immune response on neuronal functioning and the clinical 
phenotype is still unknown. Here, we attempted to block neuroinflammation by administering anti-
inflammatory agents or the selective CSF1R inhibitor PLX5622.  
 
Whereas the anti-inflammatory drugs minocycline, pioglitazone and ADIOL were unable to prevent the 
development of microgliosis, PLX5622 effectively reduced microglial numbers. Microglia were 
completely eliminated from control (>95%), but incompletely (~70%) from Mfp2-/- brain such that 
numbers of surviving microglia in Mfp2-/- mice remain higher than in vehicle-treated control mice. Based 
on transcript levels, we showed that the driver for CSF1R activation and microglial proliferation is IL-34 
but not CSF1. The incomplete microglial elimination from Mfp2-/- brain indicates that PLX5622, at this 
concentration, cannot fully block the activation of CSF1R by the strongly upregulated IL-34 [23, 25]. 
Alternatively, it is plausible that other pro-mitogenic regulators induce microgliosis in Mfp2-/- brain. 
TREM2, a cell surface receptor of the Ig-superfamily, which senses a broad class of anionic lipids and 
acts in cooperation with CSF1R to sustain microglial survival, seems to be a good candidate given the 
involvement of MFP2 in lipid metabolism [39]. It would therefore be interesting to explore whether 
TREM2 signaling is activated. It should also be noted that CSF1R blockers are well established to 
eradicate microglia in physiological conditions [21, 22, 25] but that they have been less applied in 
chronic neuroinflammatory conditions. In models of Alzheimer Disease (AD), PLX agonists were shown 
to significantly reduce microglial numbers but contradictory data were obtained whether plaque 
associated or non-associated microglia were preferentially depleted [24, 26]. In any case, 20 – 50 % 
microglia remained depending on the dose used, which is consistent with our findings. 
 
After PLX treatment, the remaining microglia in Mfp2-/- brain still adopt an inflammatory activated 
morphology. This was not surprising, given that the factors originating from neurons causing the 
microglial response are unaltered. More unexpectedly, analysis of transcript levels of several 
inflammatory markers in brain revealed that despite strong reduction of microglial numbers, the 
inflammatory responses were not substantially changed by CSF1R inhibition. Because the PLX 
treatment did neither affect number nor shape of astrocytes, we assume that the residual reactive 
microglia are the source of the unaltered inflammatory burden. We can exclude that this is triggered by 
systemic inflammation as inflammatory markers are unchanged in the circulation and in peripheral 
organs and there is no influx of monocytes into the Mfp2-/- brain ([7, 10] and unpublished data).  In order 
to compensate for the loss of most microglia in PLX-treated Mfp2-/- brain, the remaining microglia might 
produce higher levels of inflammatory markers in response to the unaltered but affected brain 
environment. In this respect, it would be interesting to analyze the remaining microglia by single cell 
sequencing approaches. Our findings diverge from those in PLX-treated AD models in which a 
substantial reduction in expression of some but not all inflammatory genes was observed in parallel 
with reduced microglial numbers [24, 26]. Also in prion-diseased mice the CSF1R inhibitor GW2580 
significantly reduced microglial proliferation as well as expression of pro-inflammatory cytokines [25]. It 
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should however be noted that levels of inflammatory markers in untreated Mfp2-/- brain are much more 
elevated than in the neurodegenerative disease models. This difference in microglial phenotype might 
explain the inefficient decrease of pro-inflammatory markers.  
 
The role of microglia in learning and memory in physiological conditions is still controversial. Several 
reports demonstrated profound defects in learning and memory processes in genetically modified 
mouse models that have dramatically reduced numbers of microglia [40, 41]. On the contrary, it was 
shown that short- and long-term microglial depletion by CSF1R inhibition does not impair explorative 
behavior, locomotion and anxiety in an OF environment, cognition by both contextual fear-conditioning 
and by the Barnes maze test, and locomotion on an accelerating rotarod [21]. Learning was even 
enhanced in mice with chronic depletion of microglia [21]. Also in our study, microglia-depleted control 
mice were able to learn the PA task significantly better than microglia-intact mice.  
 
The PLX treatment did however not improve any of the clinical parameters, neuronal dysfunction or 
behavioral deficits of MFP2-deficient mice. This contrasts with the previously mentioned studies of 
microglia depletion in neurodegenerative conditions in which the reduced inflammatory profile 
correlated with neurological improvement, enhanced memory or slower disease progression. Several 
hypotheses can be proposed to explain the failure to circumvent the clinical deterioration in Mfp2-/- mice: 
(1) Although microglial cell numbers were significantly decreased by CSF1R inhibition, the inflammatory 
activated state of the brain could not be suppressed. Consistent with this hypothesis, the remaining 
microglia in PLX-treated Mfp2-/- mice still adopt a strongly activated morphology. (2) Mfp2-/- microglia 
do not contribute to clinical deterioration and neuronal dysfunction of Mfp2-/- mice, suggesting that 
neuropathology in Mfp2-/- mice is mainly caused by neuronal deficits that cannot be suppressed by anti-
inflammatory treatments. The latter is unlikely as we previously found that neuronal dysfunction, 
locomotor activity, and explorative behavior are more severe in constitutive Mfp2-/- mice compared to 
mice with neural-specific loss of MFP2. Furthermore, we showed that the severity of clinical and 
neuronal impairments positively correlated with stronger microgliosis and a distinct aberrant microglia 
phenotype (Beckers and Baes, unpublished). (3) Other cells such as astrocytes and oligodendrocytes 
might participate in the development of neuropathology in Mfp2-/- mice. However, various reasons refute 
this hypothesis. First, astrogliosis is less pronounced compared to microgliosis in our disease model 
[9]. Second, no myelin abnormalities were found in Mfp2-/- mice which suggests that oligodendroglia 
work properly [10].  
 
Together, the inefficacy of anti-inflammatory agents to reduce microgliosis and the persistent 
inflammatory milieu despite reduced numbers of microglia after PLX treatment strongly indicates that 
the mechanisms governing neuroinflammation in MFP2 deficiency diverge from those in a 
neurodegenerative environment. It is plausible that this unstoppable inflammatory response is related 
to a unique microglial phenotype induced by the loss of MFP2 from these immune cells. A particular 
hallmark of this state is that it is accompanied by impaired neurological function but not with neuronal 
loss. It would therefore be worthwhile to further investigate the role of peroxisomal β-oxidation in 
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microglia by generating mice with microglia-selective deletion of MFP2. In summary, the strongly 
reduced numbers of reactive microglia but unchanged inflammatory environment in PLX5622 treated 
Mfp2-/- mice encumbers the outset of our studies to define the impact of microgliosis on their impaired 
neurological abilities. Still, the present findings are in agreement with our hypothesis that chronic 
neuroinflammation contributes to the neurological deterioration of these mice.   
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FIGURE LEGENDS  
Figure 1: Anti-inflammatory treatment does not suppress microgliosis nor prevent clinical 
deterioration in Mfp2-/- mice. (A) IBA1 staining of microglia (green) in inferior colliculus of Mfp2-/- and 
control mice after 6 weeks of treatment with minocycline or vehicle. Representative picture (n=4-5) (B) 
IBA1 staining of microglia (green) in brainstem of Mfp2-/- and control mice after 6 weeks of treatment 
with pioglitazone or vehicle. Representative picture (n=3). (C) Clinical deterioration of Mfp2-/- mice, 
represented by an increasing clinical score, is not restrained by pioglitazone treatment. Data of control 
mice were not shown as clinical scores were 0 for all mice at all ages. Error bars indicate SEM. n = 6-
8/group. 
 
Figure 2: Modified CSF1R signaling in Mfp2-/- mice. (A,B) Transcript levels of the Csf1 ligand (A) are 
not significantly changed whereas transcripts of the Il34 ligand (B) are significantly induced in Mfp2-/- 
mice. Transcript levels were analyzed in the brainstem of Mfp2-/- and control mice at 3 months of age. 
*Control versus Mfp2-/- : *** p<0.001, ns = not significant.  Error bars indicate SEM. n = 4/group. 
  
Figure 3: Incomplete suppression of microgliosis in Mfp2-/- mice. 16-weeks-old Mfp2-/- and control 
mice were analyzed after a 10-week PLX or vehicle treatment. (A-D) IHC overview pictures of Iba1+ 
microglial cells in the brainstem of PLX- or vehicle-treated control and Mfp2-/- mice. (E-G) Quantification 
of Iba1+ fluorescence in total brainstem (E), visual cortex (F) and thalamus (G) shows a 80-94% 
reduction in control mice and a 57-72% reduction in Mfp2-/- mice. (H-K) IHC pictures at a higher 
magnification (20X) of Iba1+ microglial cells in the visual cortex of PLX- or vehicle-treated control and 
Mfp2-/- mice. (L,M) Quantification of Iba1+ microglial cells in total brainstem (L) and total visual cortex 
(M) shows a 95-98% reduction in control mice and a 70-73% reduction in Mfp2-/- mice. *Control versus 
Mfp2-/-: ** p<0.01, *** p<0.001,**** p<0.0001.  Error bars indicate SEM. Percentages in the graphs show 
the reduction of microgliosis after PLX relative to vehicle treatment. n = 4-5/group. 
 
Figure 4: Reduction of microglial but not astroglial activation in Mfp2-/- mice after PLX treatment. 
16-weeks-old Mfp2-/- and control mice were analyzed after a 10-week PLX or vehicle treatment. (A) 
After PLX treatment, transcript levels of microglial markers are more reduced in control than in Mfp2-/- 
brainstem. Percentages in the graphs show the reduction of microglial transcripts after PLX relative to 
vehicle treatment. (D,E) Reduction of F4/80+ microglial activation in visual cortex of PLX-treated Mfp2-
/- mice (E) versus vehicle-treated Mfp2-/- mice (D). (F,G) Astrogliosis is not significantly changed 
between vehicle- (F) and PLX-treated (G) Mfp2-/- mice. Representative pictures are shown. *Control 
versus Mfp2-/- : * p<0.05, *** p<0.01, *** p<0.001.  Error bars indicate SEM. n = 4-5/group. 
 
Figure 5: PLX5622 cannot reverse the inflammatory response in Mfp2-/- CNS. Transcript level 
analysis of inflammatory markers in brainstem of 16-weeks-old Mfp2-/- and control mice were analyzed 
after a 10-week PLX or vehicle treatment. (A-B) After PLX treatment, transcript levels of Tnfa (A) and 
Il1b (B) are significantly reduced in control brain but not in Mfp2-/- brain. (C-E) Transcript levels of 
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neuroinflammatory markers Tlr2, Tspo, and 25OHChol are not altered in both genotypes after PLX 
treatment. *Control versus Mfp2-/- : * p<0.05, ns = not significant.  Error bars indicate SEM. n = 5/group. 
 
Figure 6: CSF1R inhibition does not improve clinical parameters. (A) Reduced weights of Mfp2-/- mice as 
compared to control mice are not changed by PLX treatment. (B) Clinical deterioration of Mfp2-/- mice, represented 
by an increasing clinical score, is not improved by PLX treatment. (C,D) Decreased grip strength in front paws (C) 
and all paws together (D) in Mfp2-/- mice is not improved by PLX treatment. Grip strengths were normalized to 
vehicle-treated control mice. (E) Both vehicle- and PLX-treated Mfp2-/- mice fail to remain hanging on an inverted 
grid in contrast to efficient performances of control mice. Error bars indicate SEM. n = 9/group. Veh = Vehicle. 
 
Figure 7: PLX treatment cannot prevent cognitive and behavioral impairment. (A) PLX treatment improved 
fear-conditioned learning in control mice, but did not affect the severely impaired learning in Mfp2-/- mice. (B-D) 
Explorative locomotion in an open-field environment was assessed in vehicle- and PLX-treated Mfp2-/- and control 
mice after a 10-week treatment. PLX treatment did not influence number of corner entries (B), time in center (C) 
and mean distance to center (D) in both genotypes.  *Control versus Mfp2-/- : * p<0.05, ** p<0.01, *** p<0.001, ns 
= not significant. Error bars indicate SEM. n = 9/group. 
 
Figure 8: PLX treatment does not improve affected neuronal transmission. BAEP were analyzed in the brain 
of vehicle- and PLX-treated Mfp2-/- and control mice after a 10-week treatment. (A-B) Brainstem responses were 
not altered in control (A) and Mfp2-/- mice (B) after PLX treatment. (C) Comparison of PLX-treated Mfp2-/- with PLX-
treated control mice shows that neuronal transmission is significantly delayed in Mfp2-/- mice, similar to vehicle-
treated Mfp2-/- mice. (D) Reduced amplitudes of brainstem responses in Mfp2-/- mice as compared to control mice 
are not improved by PLX treatment. *Control versus Mfp2-/- : ** p<0.01, *** p<0.001, ns = not significant. Error bars 
indicate SEM. n = 9/group. 
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